Strides Pharma gets nod to invest $15 million in its biotech arm

23 Nov 2018 Evaluate

Strides Pharma Science has received an approval from its Board of Directors to invest $15 million in its biotech arm Stelis Biopharma. The company will participate in the Series B fundraiser of Stelis Biopharma with a commitment of $15 million.

The company currently own 36.25% stake in Stelis, the former biopharma division of Strides. In the last 24 months, Stelis has advanced significantly with two of its lead assets now ready for filing in the regulated markets. The first close of the current fund raise is $35 million of which the company will commit $15 million and $20 million is from other existing shareholders.

With the first close of Series B, Stelis would have raised an equity capital of around $114 million of which Strides would have invested $37 million for an effective ownership of 38%.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

808.95 12.75 (1.60%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×